Fluicell

Fluicell Long-term Debt

Long-Term Debt of Fluicell (FLUI.ST) as of Nov 20, 2026.

Long-term Debt

0.00SEK

Last updated:

Long-Term Debt of Fluicell is 2024 0.00 SEK. Long-Term Debt of Fluicell was 2023 0.00 SEK. It decreases by % lower compared to the previous year.

The Fluicell Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2017
0.00 SEK
Jan 1, 2018
0.00 SEK
Jan 1, 2019
0.00 SEK
Jan 1, 2020
0.00 SEK
Jan 1, 2021
0.00 SEK
Jan 1, 2022
0.00 SEK
Jan 1, 2023
0.00 SEK
Jan 1, 2024
0.00 SEK
The Fluicell Long-term Debt history
YEARLong-term DebtYoY
0.00SEK—
0.00SEK—
0.00SEK—
0.00SEK—
0.00SEK—
0.00SEK—
0.00SEK—
0.00SEK—
0.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluicell Stock analysis

What does Fluicell do? Fluicell AB commercializes research tools BioPen and Dynaflow Resolve for studying, processing, and measuring drug impact on individual cells in cell-based pharmacology research. The company also develops bioprinting technology Biopixlar Retina, offering 2D and 3D options to create complex tissue-like structures with precise cell positioning control. These products target drug development research segments where individual cell analysis is critical. The primary buyers are pharmaceutical companies and research institutions focused on cell-based pharmacology. Fluicell AB's product portfolio includes BioPen, Dynaflow Resolve, and Biopixlar Retina, all designed for cell-based pharmacology research applications. The company's tools enable detailed analysis of drug effects at the single-cell level, supporting pharmaceutical research and development processes. Biopixlar Retina specifically addresses tissue engineering needs by allowing controlled creation of tissue-like structures in both 2D and 3D formats. The company's revenue streams come from selling these research tools and bioprinting technologies to pharmaceutical companies and research institutions. These segments value the precision and control offered by Fluicell's products for cell-based drug development studies. The products are positioned as essential tools for advanced cell analysis in pharmacology research environments. Fluicell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluicell stock

On Eulerpool you can find the complete historical development of Long-Term Debt Fluicell since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Fluicell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Fluicell

All Key Metrics — Fluicell